Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Friday, October 27, 2017 | Phase 3/4 Trials , Psoriasis , Research and Publications , AbbVie


Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) across all three studies versus placebo or adalimumab (based on trial design). Results were reported by Abbvie, which noted that risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

Full information about the three studies is available here.

Next Story

Comments

You must be logged in to leave a comment.